Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
15-18 September, 2025
Not Confirmed
Not Confirmed
15-18 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
15-18 September, 2025
Industry Trade Show
Not Confirmed
15-18 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
19 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eqt-to-acquire-adalvo-a-leading-b2b-dossier-developer-302508580.html
28 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-adalvo-limited-announce-licensing-agreement-for-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-ocular-inflammation-and-pain-302465602.html
16 Dec 2024
// PHARMAWEB
https://www.pharmiweb.com/press-release/2024-12-16/cnx-therapeutics-and-adalvo-announce-strategic-agreement-for-commercialisation-of-nitrofurantoin-pr
17 Jun 2024
// PHARMABIZ
13 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/13/2898123/0/en/Adalvo-Secures-First-EU-Generic-Approval-for-Liraglutide-Pre-Filled-Pen.html
09 Jan 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/zentiva-extends-its-collaboration-with-adalvo-and-strengthens-its-offering-in-respiratory-cns-and-dermatology-301716036.html
Details:
Adalvo gains exclusive rights to the commercialization of APP13007 (clobetasol propionate), for post-operative inflammation and pain following ocular surgery in the European and Brazilian markets.
Lead Product(s): Clobetasol Propionate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Steroid
Recipient: Formosa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 28, 2025
Lead Product(s) : Clobetasol Propionate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa and Adalvo Announce Licensing Deal for Clobetasol Ophthalmic Suspension
Details : Adalvo gains exclusive rights to the commercialization of APP13007 (clobetasol propionate), for post-operative inflammation and pain following ocular surgery in the European and Brazilian markets.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 28, 2025
Details:
Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.
Lead Product(s): Nitrofurantoin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Nitrofurantoin PR-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Recipient: CNX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 16, 2024
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization
Details : Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.
Product Name : Nitrofurantoin PR-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
December 16, 2024
Details:
Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Victoza-Generic
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Liraglutide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Product Name : Victoza-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
June 13, 2024
Details:
Rifamycin SV MMX (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, indicated for the treatement of Travelers’ Diarrhea.
Lead Product(s): Rifamycin Sodium,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Rifamycin SV MMX
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2024
Lead Product(s) : Rifamycin Sodium,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo Addresses Traveller’s Diarrehea with Rifamycin SV MMX
Details : Rifamycin SV MMX (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, indicated for the treatement of Travelers’ Diarrhea.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 10, 2024
Details:
Pregabalin Prolonged Release Tablets is a unique formulation helps in increasing patient's adherence, it is the backbone medication indicated in the treatment of Neuropathic pain.
Lead Product(s): Pregabalin,Inapplicable
Therapeutic Area: Neurology Brand Name: Lyrica CR-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2023
Lead Product(s) : Pregabalin,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo Announces Successful DCP Approval of Pregabalin Prolonged Release Tablets
Details : Pregabalin Prolonged Release Tablets is a unique formulation helps in increasing patient's adherence, it is the backbone medication indicated in the treatment of Neuropathic pain.
Product Name : Lyrica CR-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2023
Details:
Under the licensing agreement, Adalvo will receive from Cosmo the exclusive right to develop and commercialize Rifamycin SV MMX (rifamycin sodium) for the treatement of Travelers’ Diarrhea.
Lead Product(s): Rifamycin Sodium,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Rifamycin SV MMX
Study Phase: Approved FDFProduct Type: Antibiotic
Recipient: Cosmo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 04, 2023
Lead Product(s) : Rifamycin Sodium,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Cosmo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo & Adalvo Sign Supply Deal for Rifamycin SV MMX® 200MG Across Key Global Regions
Details : Under the licensing agreement, Adalvo will receive from Cosmo the exclusive right to develop and commercialize Rifamycin SV MMX (rifamycin sodium) for the treatement of Travelers’ Diarrhea.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 04, 2023
Details:
Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 01, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Zentiva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Details:
Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Lead Product(s): Solifenacin Succinate,Tamsulosin
Therapeutic Area: Urology Brand Name: Vesomni-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Adamed Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Adamed Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Product Name : Vesomni-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Details:
Under the agreement, Sandoz will get the rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Undisclosed
Sponsor: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Sandoz will get the rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 05, 2023
Details:
Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
Lead Product(s): Fentanyl,Inapplicable
Therapeutic Area: Neurology Brand Name: Onsolis
Study Phase: Approved FDFProduct Type: Controlled Substance
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 08, 2022
Lead Product(s) : Fentanyl,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Acquisition
Adalvo Acquires Its First Branded Product, Onsolis
Details : Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
Product Name : Onsolis
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 08, 2022
ABOUT THIS PAGE